Distsirkulyatornaya entsefalopatiya: klinika, diagnostika i vozmozhnosti terapii


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the main clinical and neurological signs of discirculatory encephalopathy (DE). The approaches to the treatment of DE aimed at correcting the risk factors for its development, improving cerebral blood flow and metabolism of the brain are consi-dered.

全文:

受限制的访问

作者简介

E. Astashkin

Email: 287ast@mail.ru

M. Glezer

Email: 287ast@mail.ru

参考

  1. Huang W.S., Tseng C.H., Lin C.L., Lin C.Y., S ung F.C., Kao C.H. Risk of subsequent dementia in patients with hypertensive encephalopathy: a nationwide population-based study in Taiwan Dement Geriatr. Cogn. Disord. 2014;37(5-6)357-65.
  2. Chung T. T. Lin C. Y., Huang W. Y.,Lin C.L,Sung F.C., Kao C.H. Risks of subsequent epilepsy among patients with hypertensive encephalopathy: a nationwide population-based study. Epilepsy. Behav. 2013;29(2):374-78.
  3. Стаховская Л.В., Гудкова В.В. Дисциркуляторная энцефалопатия: терминология, патогенез, клиническая картина. Справочник поликлинического врача. 2010;10:59-61.
  4. Taylor F., Huffman M.D., Macedo A.F., Moore T.H., Burke M., Davey Smith G., Ward K., Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst.Rev. 2013;1:CD004816.
  5. Stone N.J., Robinson J.G, Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C. Jr., Watson K., Wilson P.W. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2014;63(25 Pt B):2889-934.
  6. Satoh M., Takahashi Y., Tabuchi T., Minami Y., Tamada M., Takahashi K., Itoh T., Morino Y., Nakamura M. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin. Sci. (Lond). 2015;129(2):93-105.
  7. Macedo A.F., Taylor F.C., Casas J.P., Adler A., Prieto-Merino D., Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and metaanalysis. BMC Med. 2014;12:51.
  8. Swiger K.J., Manalac R.J., Blumenthal R.S., Blaha M.J., Martin S.S. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin. Proc. 2013;88(11):1213-21.
  9. Ott B.R.,Daiello L.A., DahabrehI J.,Springate B.A., Bixby K., Murali M., Trikalinos T.A. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J. Gen. Intern. Med. 201530(3)348-58.
  10. McGuinness B., O'Hare J., Craig D., Malouf R., Passmore P. Statins for the treatment of dementia. Cochrane Database Syst. Rev. 2010;(8):CD007514.
  11. Давидович И.М., Афонасков О.В. Артериальная гипертензия у мужчин молодого возраста, офицеров сухопутных войск: психофизиологические особенности. Вестник Росздравнадзора. 2012;5:51-6.
  12. Maxwell C.J., Hogan D.B., Ebly E.M. Calciumchannel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1999;161(5):501-6.
  13. Chang-Quan H., Hui W., Chao-Min W., Zheng-Rong W.,Jun-Wen G., Yong-Hong L., Yan-You L., Qing-Xiu L. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int. J. Clin. Pract. 2011;65(12): 1295-305.
  14. McGuinness B., Todd S., Passmore P., Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst. Rev. 2006;(2):CD004034.
  15. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.
  16. Peters R., Beckett N., Forette F., Tuomilehto J., Clarke R., Ritchie C., Waldman A., Walton I., Poulter R., Ma S., Comsa M., Burch L., Fletcher A., Bulpitt C.; HYVET investigators. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-89.
  17. Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhаger W.H., Babarskiene M.R., Babeanu S., Bossini A., Gil-Extremera B., Girerd X., Laks T., Lilov E., Moisseyev V., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Fagard R. Prevention of dementia in randomised double-blind placebocontrolled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-51.
  18. Lopez-Arrieta J.M., Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. 2001;(1):CD000147.
  19. Trompet S., Westendorp R.G., Kamper A.M., de Craen A.J. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol. Aging. 2008;29(2):306-8.
  20. Yasar S., Zhou J., Varadhan R., Carlson M.C. The use of angiotensin-converting enzyme inhibitors and diuretics is associated with a reduced incidence of impairment on cognition in elderly women. Clin. Pharmacol. Ther. 2008;84(1):119-26.
  21. Hajjar I., Hart M., Chen Y.L., Mack W., Milberg W., Chui H., Lipsitz L. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch. Intern. Med. 2012;172(5):442-44.
  22. Hajjar I., Hart M., Milberg W., Novak V., Lipsitz L. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr. 2009;9:48.
  23. Fogari R., Mugellini A., Zoppi A., Lazzari P., Destro M., Rinaldi A., Preti P. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J. Hum. Hypertens. 2006;20(3):177-85.
  24. Янсен В., Брукнер Г.В. Лечение хронической цереброваскулярной недостаточности с использованием драже Актовегин форте (двойное слепое плацебо-контролируемое исследование). РМЖ. 2002; 10(12-13):543-46.
  25. Летцел Х., Шиктигер У. Применение Актовегина у пожилых пациентов с органическими синдромами. Мультицентровое исследование 1549 пациентов. РМЖ. 2003;11(25):1428-31.
  26. Шавловская О.А. Применение Актовегина при нейропротективной терапии больных с цереброваскулярными заболеваниями. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(6):74-6.
  27. Guekht A., Skoog I., Korczyn A.D., Zakharov V., Eeg M., Vigonius U. A Randomised, DoubleBlind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. Dement Geriatr. Cogn. Dis. Extra. 2013;3(1):459-67.
  28. Elmlinger M.W., Kriebel M., Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular. Med. 2011;13(4):266-74.
  29. Асташкин Е.И., Глезер М.Г., Винокуров М.Г., Егорова Н.Д., Орехова Н.С., Новикова А.Н., Грачев С.В., Юринская М.М., Соболев К.Э. Актовегин снижает уровень радикалов кислорода в образцах цельной крови пациентов с сердечной недостаточностью и подавляет развитие некроза перевиваемых нейронов человека линии SK-N-SH. Доклады Академии наук. 2013;448(2):232-35.
  30. Юринская М.М., Винокуров М.Г., Грачев С.В., Асташкин Е.И. Актовегин снижает апоптоз клеток нейробластомы SK-N-SH, индуцированный пероксидом водорода, в результате ингибирования p38MAPK и P1-3K. Доклады Академии наук. 2014; 456(5):618-21.
  31. Асташкин Е.И., Глезер М.Г., Орехова Н.С., Егорова Н.Д., Грачев С.В., Соколова И.Н. Влияние Актовегина на фагоциты крови при оксидативном стрессе у пациентов с сердечной недостаточностью. Фарматека. 2014;9:14-9.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##